Relevance of biomarkers across different neurodegenerative diseases.,Alzheimer's Research & Therapy

当前位置： X-MOL 学术 › Alz. Res. Therapy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Relevance of biomarkers across different neurodegenerative diseases.
Alzheimer's Research & Therapy ( IF 8.823 ) Pub Date : 2020-05-13 , DOI: 10.1186/s13195-020-00601-w
Alexander J Ehrenberg _{1,

2,

3} , Ayesha Khatun ₄ , Emma Coomans ₅ , Matthew J Betts _{6,

7} , Federica Capraro _{8,

9} , Elisabeth H Thijssen _{1,

10} , Konstantin Senkevich _{11,

12} , Tehmina Bharucha ₁₃ , Mehrsa Jafarpour ₁₄ , Peter N E Young _{15,

16} , William Jagust _{3,

17} , Stephen F Carter _{18,

19} , Tammaryn Lashley _{14,

20} , Lea T Grinberg _{1,

21,

22} , Joana B Pereira _{23,

24} , Niklas Mattsson-Carlgren _{15,

16} , Nicholas J Ashton _{15,

16,

25,

26} , Jörg Hanrieder _{14,

15} , Henrik Zetterberg _{14,

15,

27,

28} , Michael Schöll _{14,

15,

24} , Ross W Paterson ₄

Affiliation

Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Department of Integrative Biology, University of California, Berkeley, Berkeley, CA, USA.
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.
Dementia Research Centre, University College London Institute of Neurology, London, UK.
Department of Radiology & Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam Neuroscience, Amsterdam, The Netherlands.
German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Institute of Cognitive Neurology and Dementia Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.
The Francis Crick Institute, London, UK.
Department of Neuromuscular Diseases, University College London Queen Square Institute of Neurology, London, UK.
Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands.
Petersburg Nuclear Physics Institute names by B.P. Konstantinov of National Research Center, Kurchatov Institute, St. Petersburg, Russia.
First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia.
Oxford Glycobiology Institute, Department of Biochemistry , University of Oxford, Oxford, UK.
Department of Neurodegenerative Disease, UCL Queen Square, Institute of Neurology, University College London, London, UK.
Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Wallenberg Center for Molecular and Translational Medicine, Lund University, Lund, Sweden.
Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Wolfson Molecular Imaging Centre, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.
Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.
University of São Paulo Medical School, São Paulo, Brazil.
Global Brain Health Institute, San Francisco, CA, USA.
Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
UK Dementia Research Institute at University College London, London, UK.

BACKGROUND The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer's disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field. PURPOSE OF REVIEW Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer's Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care.

中文翻译：

生物标志物在不同神经退行性疾病中的相关性。

背景技术可用于神经退行性疾病研究的基于流体和成像的生物标志物的面板正在增长，并且具有弥合研究和临床中重要差距的潜力。随着这种增长和越来越多的使用，适当的实现和解释至关重要。在研究疾病的病因和临床效用时，各种生物标记物在强度，局限性和偏倚方面存在细微的差异。例如，阿尔茨海默氏病发病机理的神经病理学研究可能与基于生物标记物的研究得出的结论不一致。考虑不同研究方法和方法的不同优势，局限性和偏见，可能有助于协调神经退行性疾病领域内的学科。审查的目的以及本期《阿尔茨海默氏症研究与治疗》中涉及液体和成像生物标志物的单独评论文章，我们还将介绍伦敦大学学院2019年神经退行性疾病中生物标志物课程的讨论结果。在这里，我们讨论了在神经退行性疾病研究中使用生物标志物的主题，并评论了在不同神经退行性疾病中的合理使用，解释和考虑因素。我们还提请注意可将生物标志物与其他学科结合使用的领域，以了解痴呆症的病理生理学和病因学问题。最后，我们重点介绍了在神经退行性疾病研究和护理领域已提出的新模式。

更新日期：2020-05-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>